Shenzhen Neptunus Bioengineering Co

Shenzhen Neptunus Bioengineering Co Operating Cash Flow

The Operating Cash Flow of Shenzhen Neptunus Bioengineering Co (000078.SZ) as of Oct 18, 2026 is 104.39 M CNY. In the previous year, Operating Cash Flow was 39.54 M CNY — a change of 164.02% (higher).

Operating Cash Flow

104.39 MCNY

YoY

164.02%

Last updated:

Operating Cash Flow of Shenzhen Neptunus Bioengineering Co is 2025 104.39 M CNY. Operating Cash Flow of Shenzhen Neptunus Bioengineering Co was 2024 39.54 M CNY. It decreases by 164.02% higher compared to the previous year.

The Shenzhen Neptunus Bioengineering Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-1.14 B CNY
Jan 1, 2019
2.27 B CNY
Jan 1, 2020
1.65 B CNY
Jan 1, 2021
866.12 M CNY
Jan 1, 2022
-64.33 M CNY
Jan 1, 2023
-410.19 M CNY
Jan 1, 2024
39.54 M CNY
Jan 1, 2025
104.39 M CNY
The Shenzhen Neptunus Bioengineering Co Operating Cash Flow history
YEAROperating Cash FlowYoY
104.39 MCNY+164.02%
39.54 MCNY-109.64%
-410.19 MCNY+537.65%
-64.33 MCNY-107.43%
866.12 MCNY-47.53%
1.65 BCNY-27.24%
2.27 BCNY-299.85%
-1.14 BCNY-53.34%
-2.43 BCNY+62.52%
-1.50 BCNY-1,754.01%
90.51 MCNY-177.04%
-117.48 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Shenzhen Neptunus Bioengineering Co Stock analysis

What does Shenzhen Neptunus Bioengineering Co do? Shenzhen Neptunus Bioengineering Co Ltd is a company based in Shenzhen, China, operating within the Health Care sector. The company has been publicly traded since its IPO on December 18, 1998, with a ticker symbol of 000078.SZ and ISIN CNE000000X95. It employs 9,874 people. The company's primary business involves the pharmaceutical industry, focusing on the development and distribution of various medical products. Its main product categories include anti-tumor medications, cardiovascular drugs, marine-derived pharmaceuticals, respiratory treatments, anti-infective products, and additional pharmaceuticals. The company also offers healthcare products, health food, and medical instruments. Shenzhen Neptunus Bioengineering Co Ltd primarily serves the domestic Chinese market, with a significant focus on the East China region. The company's official website is https://www.neptunusbio.com/. No additional details regarding founding year, specific acquisitions, or financial figures beyond the provided data are included in this profile. Shenzhen Neptunus Bioengineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shenzhen Neptunus Bioengineering Co stock

Operating Cash Flow of Shenzhen Neptunus Bioengineering Co is 104.39 M CNY in 2025.

Operating Cash Flow of Shenzhen Neptunus Bioengineering Co changed from 39.54 M CNY to 104.39 M CNY, representing a 164.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Shenzhen Neptunus Bioengineering Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Shenzhen Neptunus Bioengineering Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Shenzhen Neptunus Bioengineering Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Shenzhen Neptunus Bioengineering Co